Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Bexson Biomedical

1 Drug Candidate

Bexson Biomedical is a US private biotech developing BB106, a subcutaneous wearable formulation of ketamine delivered via its proprietary SEVALENT™ platform device. The formulation is designed to provide precise, extended ketamine dosing for chronic pain and depression outside of clinic settings. As of 2023 the company was conducting IND-enabling studies.

Drug Pipeline

1

BB106 (subcutaneous ketamine)

Ketamine
Pre-clinical
Major Depressive Disorder (MDD)

Subcutaneous wearable ketamine (SEVALENT™ platform) for chronic pain and depression; IND-enabling studies as of 2023.

Quick Facts

Type
Private Biotech
Lead Stage
Pre-clinical
Website
Visit